Please select the eligibility criteria that correspond to the clinical trial below.
Title: Human Recombinant Erythropoietin (HrEPO) in Asphyxia Neonatorum: A Pilot Trial
Brief Summary: In this prospective trial the investigators plan to study the efficacy of erythropoietin as a therapeutic agent in neonates who suffer from brain injury following perinatal asphyxia.


Options:
A: Inclusion Criteria:

* Mothers must have consented for cord blood collection at delivery
* cord blood must be available for extraction of stem cells.
* \>34 weeks gestation
* cord or neonatal pH\<7.0 or base deficit\>16 milliequivalents per liter (mEq/L) or history of acute perinatal event
* either a 10 minute Apgar \< 5 or continued need for ventilation.
* All infants must have signs of encephalopathy within 6 hours of age.

Exclusion Criteria:

* Inability to enroll by 14 days of age.
* Presence of known chromosomal anomaly.
* Presence of major congenital anomalies.
* Severe intrauterine growth restriction (weight \<1800g)
* Infants in extremis for whom no additional intensive therapy will be offered by attending neonatologist.
* Parents refuse consent.
* Attending neonatologist refuses consent.
* Failure to collect the infant's cord blood and/or laboratory unable to process cord blood.
B: Inclusion Criteria:

* Inborn infants at term gestation (38-42 weeks)
* Apgar score ≤ 3 at 5 minutes and/or delayed first breath beyond five minutes after birth
* Profound metabolic or mixed acidosis with serum bicarbonate \<12 mMol/L in initial arterial blood gas
* Evidence of encephalopathy such as stupor, coma, seizures, or hypotonia in the immediate neonatal period

Exclusion Criteria:

* Twin gestation
* Maternal diabetes
* Congenital malformations of the central nervous system
* Chromosomal abnormalities
* Chorioamnionitis and congenital infections
* Intrauterine growth restriction
C: Inclusion Criteria:

* Birth weight range: 500g\~1250g
* Fetal gestational age: 23 weeks to 29 weeks
* Premature infants who cannot do spontaneous breathing, which ventilation rate is less than 12 breaths per min of ventilation rate and 25% of oxygen demand
* Premature infants who does not improve the breathing or worse within 24 hours prior to enrollment of this study
* Written consent form signed by a legal representative or a parent

Exclusion Criteria:

* Cyanotic or acyanotic congenital heart diseases except patent ductus arteriosus
* Severe lung malformation (i.e. Pulmonary hypoplasia, congenital diaphragmatic hernia, congenital cystic lung disease)
* Severe lung malformation with chromosome anomalies (i.e. Edward syndrome, Patau syndrome, Down syndrome, etc) or severe congenital malformation (Hydrocephalus, Encephalocele, etc)
* Severe congenital infection (i.e. Herpes, Toxoplasmosis, Rubella, Syphilis, AIDS, etc)
* CRP \> 30 mg/dL; Severe sepsis or shock
* Premature infants who is going to or expected to have surgery 72 hours before/after this study drug administration
* Surfactant administration within 24 hours prior to this study drug administration
* Severe intracranial hemorrhage ≥ grade 3 or 4
* Premature infants who have active pulmonary hemorrhage or active air leak syndrome at the time point of screening
* History of other clinical studies as a participant
* Premature infants who are allergic to Gentamicin
* Premature infants who is considered inappropriate by the investigators
D: Inclusion Criteria:

1. ≥ 36 weeks gestational age
2. Perinatal depression (low Apgar score, need for resuscitation)
3. Moderate to severe encephalopathy

Exclusion Criteria:

1. Specific aEEG findings
2. Intrauterine growth restriction
3. Severe congenital anomaly, genetic syndrome, metabolic disorder, arthrogryposis, TORCH infection
4. Microcephaly
5. Infant older than 23.5 hours of age at the time of consent
6. Infant judged by an attending physician to be likely to die due to the severity of illness
7. Polycythemia
8. Hypertension
9. No in-dwelling line

Answer: B